Over the past days, ImmunoCellular Therapeutics Ltd (OTC:IMUC) has been jumping up and down instantly. Yesterday, the 
stock price decreased again by 7.27%, while its traded volume notably rose up. Though, what’s behind the price hesitations is not clear yet.
According to the records, the latest news by ImmunoCellular came up on Monday, when they said that Miss Helen Kim has been appointed to the Company’s Board of Directors and has been elected to the company’s Board of Directors and a Chairperson of its Product Strategic Committee.
The new appointment is based on Ms. Kim’s experience in the industry and aims to bring new investments on board. Though, it is too soon for any final conclusions.
IMUC is a LA-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.[BANNER] According to its 10-Q report for the period ended June 30, 2011, the company’s cash and cash equivalents increased significantly, though its accumulated deficit exceeded $27 million. At the same time, the net loss remained substantially high and the revenues continued pointing $nil.
Based on these results, management believe that their existing capital will be sufficient to fund their operations for at least the next twelve months. However, they do not currently anticipate deriving any revenues from either product sales or licensing during the foreseeable future. Thus, the team will need to obtain additional funds through various financing sources.
